Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 8/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3253689 | 0.86 | MEN1 (0.43) | MTNR1AMTNR1B | |
| SCHEMBL3244758 | 0.77 | MTNR1A (0.57) | MTNR1AMTNR1B | |
| SCHEMBL3253551 | 0.76 | MTNR1A (0.56) | MTNR1AMTNR1B | |
| Dimethylamine SCHEMBL3263624 | 0.73 | MTNR1A (0.50) | MTNR1AMTNR1BKDM4EHSD17B10HPGD | |
| SCHEMBL3248497 | 0.68 | MTNR1A (0.59) | MTNR1AMTNR1B | |
| SCHEMBL3245162 | 0.67 | MTNR1A (0.46) | MTNR1AMTNR1BKDM4EHSD17B10HPGD | |
| SCHEMBL14177908 | 0.64 | MTNR1A (0.42) | MTNR1AMTNR1BKDM4EHSD17B10HPGD | |
| SCHEMBL7547846 | 0.63 | HTR1A (0.61) | — | |
| SCHEMBL28753859 | 0.63 | HTR1A (0.61) | — | |
| SCHEMBL29449354 | 0.63 | KDM4E (0.48) | MTNR1AMTNR1BKDM4EHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537113-B9 | ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LTD (IN) | 2010-05-26 | — | — | EP | claimed |
| EP-1537113-B1 | ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LTD (IN) | 2009-10-07 | — | — | EP | claimed |
| US-7297711-B2 | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2007-11-20 | — | — | US | claimed |
| US-20050203103-A1 | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2005-09-15 | — | — | US | claimed |
| EP-1537113-A1 | ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Suven Pharmaceuticals Ltd. (IN) | 2005-06-08 | — | — | EP | claimed |
| WO-2004000845-A1 | ARYLALKYL INDOLES HAVING SERTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LIMITED (IN) | 2003-12-31 | — | — | WO | claimed |
| EP-1537113-B9 | ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LTD (IN) | 2010-05-26 | — | — | EP | disclosed |
| EP-1537113-B1 | ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LTD (IN) | 2009-10-07 | — | — | EP | disclosed |
| US-7297711-B2 | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2007-11-20 | — | — | US | disclosed |
| US-20050203103-A1 | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203103-A1 | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | TPH1, HTR1A, HTR7 | MTNR1A 76/4885MTNR1B 105/4885L3MBTL1 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.